Skip to Content
 

News: Immunotherapy

Study identifies critical regulator of tumor-specific T cell differentiation

Saturday, June 29th, 2019

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work

Immunotherapy helping 87-year-old man stay on the job

Friday, June 7th, 2019

Immunotherapy is helping cancer patient Roszell Mack Jr. to continue going to his job on a Kentucky horse farm.

VICC launches new telehealth program for CAR-T patients

Monday, March 4th, 2019

Some cancer patients receiving CAR-T infusions can now avoid hospital stays because of a telemedicine program launched by Vanderbilt-Ingram Cancer Center.

Discovery points to new cancer immunotherapy option

Monday, February 25th, 2019

Researchers have discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

Research team documents potential new treatment path for breast cancer

Friday, January 18th, 2019

Immunotherapies that take off the “brakes” on the adaptive anti-tumor response have worked well in melanoma and lung cancer but less so in breast cancers. That could change.

Breast cancer-killing RIG

Friday, December 14th, 2018

A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer.

Immunotherapies linked to specific heart complications

Tuesday, November 20th, 2018

Cardiovascular complications linked to immune checkpoint inhibitors include myocarditis, pericarditis, vasculitis and arrhythmias and occur early in the course of treatment, Vanderbilt researchers report.

Team’s findings show glutamine metabolism affects T cell signaling

Monday, November 5th, 2018

A drug currently in clinical trials as an anticancer agent might also be useful as a treatment for inflammatory and autoimmune diseases. The findings also suggests strategies for using the drug to enhance cancer immunotherapies.

Combination therapy improves small-cell lung cancer survival

Friday, October 26th, 2018

Patients who received atezolizumab in addition to standard chemotherapy lived two months longer than those treated with chemotherapy alone, according to a recent study published in the New England Journal of Medicine.

Study tracks incidence, timing of immunotherapy-related deaths

Thursday, September 13th, 2018

Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.

Next Page »